CELEX: 62017TA0182
Language: en
Date: 2018-09-25 00:00:00
Title: Case T-182/17: Judgment of the General Court of 25 September 2018 — Novartis v EUIPO — Chiesi Farmaceutici (AKANTO) (EU trade mark — Opposition proceedings — Application for EU word mark AKANTO — Earlier EU word mark KANTOS — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EC) No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001)

12.11.2018   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 408/50
            
         
      Judgment of the General Court of 25 September 2018 — Novartis v EUIPO — Chiesi Farmaceutici (AKANTO)
      (Case T-182/17) (1)
      
      ((EU trade mark - Opposition proceedings - Application for EU word mark AKANTO - Earlier EU word mark KANTOS - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001))
      (2018/C 408/64)
      Language of the case: English
      
         Parties
      
      
         Applicant: Novartis AG (Basel, Switzerland) (represented by: L. Junquera Lara, lawyer)
      
         Defendant: European Union Intellectual Property Office (represented initially by: P. Duarte Guimarães and J. Ivanauskas, and subsequently by J. Ivanauskas and D. Walicka, acting as Agents)
      
         Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Chiesi Farmaceutici SpA (Parma, Italy) (represented by: T. de Haan, P. Péters, and F. Folmer, lawyers)
      
         Re:
      
      Action brought against the decision of the First Board of Appeal of EUIPO of 9 January 2017 (Case R 531/2016-1) relating to opposition proceedings between Chiesi Farmaceutici and Novartis.
      
         Operative part of the judgment
      
      The Court:
      
                  1.
               
               
                  Dismisses the action;
               
            
                  2.
               
               
                  Orders Novartis AG to pay the costs.
               
            
         (1)  OJ C 161, 22.5.2017.